Autism Diagnostics Lab Launches Non-Invasive Urine Screening Test

The MDM Gut & Brain Health Test analyzes a proprietary panel of metabolites linked to gut-brain interactions, which researchers identified as significant biomarkers for autism. According to studies published in the journal Molecular Psychiatry, the panel achieved 90% sensitivity and 100% specificity in distinguishing children with autism from typically developing peers during initial research phases. The technology stems from over 25 years of investigation into the relationship between the gut microbiome and neurodevelopment, led by James Adams, Ph.D., who serves as both a professor at Arizona State University and President of Autism Diagnostics Lab.

Families can collect samples at home, with results typically processed through the company's CLIA-certified network within 7–10 business days. While the test provides biological data to help clinicians identify children who may require further developmental evaluation, the company emphasizes that it is not a standalone diagnostic tool. Clinical diagnosis remains the responsibility of healthcare professionals using established criteria. By introducing this metabolomics-based approach, the lab hopes to alleviate some of the pressure on current diagnostic pathways, which often involve long wait lists and reliance solely on behavioral assessments.